These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35890100)

  • 1. Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque.
    Basiak M; Kosowski M; Hachula M; Okopien B
    Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque.
    Kosowski M; Basiak M; Hachuła M; Okopień B
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods.
    Basiak M; Hachula M; Kosowski M; Machnik G; Maliglowka M; Dziubinska-Basiak M; Krysiak R; Okopien B
    Molecules; 2023 Aug; 28(15):. PubMed ID: 37570897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Concentrations of Cytokines in Patients with Combined Hyperlipidemia and Atherosclerotic Plaque before Treatment Initiation-A Pilot Study.
    Basiak M; Kosowski M; Hachula M; Okopien B
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630041
    [No Abstract]   [Full Text] [Related]  

  • 5. Pleiotropic Effects of PCSK-9 Inhibitors.
    Basiak M; Kosowski M; Cyrnek M; Bułdak Ł; Maligłówka M; Machnik G; Okopień B
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators.
    Rajavashisth TB; Xu XP; Jovinge S; Meisel S; Xu XO; Chai NN; Fishbein MC; Kaul S; Cercek B; Sharifi B; Shah PK
    Circulation; 1999 Jun; 99(24):3103-9. PubMed ID: 10377072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Concentrations of New Biochemical Markers of Atherosclerosis in Patients with Dyslipidemia-A Pilot Study.
    Kosowski M; Basiak M; Hachuła M; Okopień B
    Medicina (Kaunas); 2022 May; 58(6):. PubMed ID: 35743980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein oxidation may underlie the paradoxical association of low cholesterol with coronary atherosclerotic risk in rheumatoid arthritis.
    Karpouzas GA; Ormseth SR; Ronda N; Hernandez E; Budoff MJ
    J Autoimmun; 2022 May; 129():102815. PubMed ID: 35366608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
    Tang ZH; Peng J; Ren Z; Yang J; Li TT; Li TH; Wang Z; Wei DH; Liu LS; Zheng XL; Jiang ZS
    Atherosclerosis; 2017 Jul; 262():113-122. PubMed ID: 28535426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties.
    Wang SS; Hu SW; Zhang QH; Xia AX; Jiang ZX; Chen XM
    PLoS One; 2015; 10(8):e0136026. PubMed ID: 26288013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.
    Ogata A; Oho K; Matsumoto N; Masuoka J; Inoue K; Koguchi M; Yoshioka F; Abe T
    Acta Neurochir (Wien); 2019 Mar; 161(3):597-600. PubMed ID: 30729307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE(-/-) mice by activating PI3K/AKT signaling and suppressing TRL4/NF-κB signaling.
    Wang N; Zhang X; Ma Z; Niu J; Ma S; Wenjie W; Chen J
    Biomed Pharmacother; 2020 Mar; 123():109729. PubMed ID: 31887543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study.
    Ko DT; Khan AM; Kotrri G; Austin PC; Wijeysundera HC; Koh M; Chu A; Jackevicius CA; Lawler PR; Tu JV
    J Am Heart Assoc; 2018 Nov; 7(21):e010007. PubMed ID: 30571382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cluster of Differentiation 147 (CD147) serves as a promoter of atherosclerosis in patients with cerebral infarction.
    Wang GJ; Dong X; Li Y
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5710-5717. PubMed ID: 36066144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
    Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS
    Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
    Liang D; Li C; Tu Y; Li Z; Zhang M
    Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention.
    Robinson JG; Heistad DD; Fox KA
    Atherosclerosis; 2015 Dec; 243(2):593-7. PubMed ID: 26545013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between TLR4/NF-κB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability.
    Gargiulo S; Gamba P; Testa G; Rossin D; Biasi F; Poli G; Leonarduzzi G
    Aging Cell; 2015 Aug; 14(4):569-81. PubMed ID: 25757594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis.
    Wu Z; Gao L; Lin Z
    Am J Transl Res; 2023; 15(1):452-465. PubMed ID: 36777825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.